FBLG FIBROBIOLOGICS INC.

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond.

Details of the conference and presentations are as follows:

The Cell & Gene Meeting On The Med

Presentation Title: Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases

Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics

Location: Salone dei Cavalieri, Section 2

Date and Time: Wednesday, April 16 at 9:00 AM CEST

For more information, please visit FibroBiologics' or email FibroBiologics at: .

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit .

General Inquiries:

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697



EN
11/04/2025

Underlying

FBLGFIBROBIOLOGICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIBROBIOLOGICS INC.

 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Reports First Quarter 2025 Financial Results and Provid...

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025 HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-d...

May 14, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Presenting at the ThymUS 2025 Meeting

FibroBiologics Presenting at the ThymUS 2025 Meeting HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the taking place in Lihue, Kaua'i Hawaii from April 27 - May 1, 2025. Founded in 2001, ThymUS brings together internatio...

April 29, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterran...

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell &...

April 11, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pu...

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology HOUSTON, April 08, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials...

April 8, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur ...

FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt HOUSTON, April 03, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (im Folgenden kurz „FibroBiologics“), ein im klinischen Stadium tätiges Biotechnologieunternehmen mit über 240 erteilten und angemeldeten Patenten für die Entwicklung von Therapeutika und potenziellen Heilmitteln für chronische Krankheiten mithilfe von Fibroblasten und von Fibroblasten abgeleiteten Materialien, hat heute einen signifikanten Fortschritt in der Erforschung neurodegenerativer Erkrankungen bekannt gegeben....

April 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch